Tilrekimig for moderate to severe eczema in people aged 12 and older
Tests tilrekimig against dupilumab and placebo in people with moderate to severe eczema.
Plain-language title generated from the registry record
Registry title: A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
Key facts
- Where
- Arlington, Bakersfield, Birmingham, Boise, Bryant, Camp Hill, Dallas, East Syracuse, Fountain Valley, Hialeah, Hunt Valley, Huntington Beach, Indianapolis, Laguna Niguel, Los Angeles, Macon, Marietta, Memphis, Miami, Miami Lakes, Northridge, Orlando, Phoenix, Portland, Santa Ana, Southlake, Sugar Land, Tampa, Troy, Tulsa, and Ypsilanti, United StatesSee the 34 sites
- Phase
- Phase 3
Where in United States
- Alexandria Associates in DermatologyArlington, United StatesTaking people
- Arlington Research CenterArlington, United StatesTaking people
- Kern Research, IncBakersfield, United StatesTaking people
- AllerVie Clinical ResearchBirmingham, United StatesTaking people
- Cahaba Dermatology Skin Health CenterBirmingham, United StatesNot yet recruiting
- Treasure Valley Medical ResearchBoise, United StatesNot yet recruiting
- Dermatology Trial Associates, Inc.Bryant, United StatesTaking people
- Best Skin Research, LLCCamp Hill, United StatesNot yet recruiting
- Derm TexasDallas, United StatesTaking people
- Dermatology Treatment and Research CenterDallas, United StatesTaking people
- Empire DermatologyEast Syracuse, United StatesNot yet recruiting
- First Oc Dermatology Research IncFountain Valley, United StatesNot yet recruiting
- Direct Helpers Research CenterHialeah, United StatesTaking people
- Maryland Laser Skin and VeinHunt Valley, United StatesTaking people
- Marvel Clinical ResearchHuntington Beach, United StatesTaking people
- Dawes Fretzin Clinical Research Group, LLCIndianapolis, United StatesTaking people
- Avance Clinical TrialsLaguna Niguel, United StatesTaking people
- California Allergy & Asthma Medical GroupLos Angeles, United StatesTaking people
- Skin Care Physicians of GeorgiaMacon, United StatesTaking people
- Marietta Dermatology Clinical Research, Inc.Marietta, United StatesTaking people
- Clinical Neuroscience Solutions, LLC.Memphis, United StatesTaking people
- Research Associates of South Florida, LLCMiami, United StatesTaking people
- Global Health Research Center, Inc.Miami Lakes, United StatesTaking people
- Northridge Clinical Trials, LLCNorthridge, United StatesTaking people
- Clinical Neuroscience Solutions, LLCOrlando, United StatesTaking people
- Alliance Dermatology & MOHS CenterPhoenix, United StatesTaking people
- Oregon Medical Research CenterPortland, United StatesNot yet recruiting
- Wolverine Clinical TrialsSanta Ana, United StatesNot yet recruiting
- Stryde Research-Epiphany DermatologySouthlake, United StatesNot yet recruiting
- Complete DermatologySugar Land, United StatesTaking people
- Advanced Clinical Research InstituteTampa, United StatesNot yet recruiting
- Revival Research Institute, LLCTroy, United StatesNot yet recruiting
- Vital Prospects Clinical Research Institute., PCTulsa, United StatesTaking people
- Respiratory Medicine Research Institute of Michigan, PLCYpsilanti, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pfizer
- Trial code
- NCT07783425EU 2026-525743-32-00
- Record updated
- 6 November 2026
- Original description
The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body in adults and adolescents with moderate to severe atopic dermatitis (eczema). Eczema is a condition which can cause dryness, itching, and redness of your skin.Read full original descriptionShow less
A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, ACTIVE- AND PLACEBO-CONTROLLED PHASE 3 MONOTHERAPY STUDY WITH MAINTENANCE PERIOD TO INVESTIGATE THE EFFICACY AND SAFETY OF TILREKIMIG IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body in adults and adolescents with moderate to severe atopic dermatitis (eczema). Eczema is a condition which can cause dryness, itching, and redness of your skin.
The study is seeking participants who:
* Are aged 12 years or older. * Were confirmed to have atopic dermatitis (AD) at least 12 months ago. * Are not having an effective treatment result from medicines that are applied on skin for AD. * Are considered by their doctors to have moderate to severe AD.
The study treatment period will be 52 weeks. During the 24-week initial treatment period, participants will be randomized to one of three study treatments - tilrekimig, dupilumab, or placebo. Placebo does not have any medicine in it but looks just like the medicine being studied. These treatments will be randomized based on a 2:2:1 ratio. This means out of 1375 participants, about 550 participants will receive tilrekimig, 550 will receive dupilumab, and 275 will receive placebo. This will be followed by a 28-week maintenance period. The last dose of study treatment will be administered at week 48.
Some participants will join the long-term extension (LTE) study C4531008 at week 52. A long-term extension study is an additional study that some participants may be able to join after completing the study if they are interested and meet eligibility requirements. It allows researchers to continue collecting information about how well the study medicine works. It also helps them assess how safe it is when used for a longer period of time. Participants who do not join this study will enter a 12-week safety follow-up period. This period ends 16 weeks after their last dose of study treatment.
Inclusion: You are [12] years of age or older; You have had moderate-to-severe eczema for at least 1 year; Topical medicines for eczema have not worked well for you.
Exclusion: Clinically Significant Autoimmune Disease; Significant Infection History or Active Infection; Significant psychiatric illness or suicidality; Known or Suspected Immunodeficiency/Immunosuppression; Clinically significant hepatic, renal, or hematologic abnormalities.